Receptor tyrosine kinase (RTK) inhibitors yielded no-to-low objective responses, although a considerable proportion (~40%) of ACC tumors did harbor alterations in tyrosine kinase genes [8,25]. Here, NTRK1 is linked to adrenal cortex carcinoma.